Cresemba costs roughly $1,620 for a 14-count supply of capsules at the wholesale level, before any insurance or discounts. That price reflects a combination of factors: it treats rare, life-threatening fungal infections with a small patient population, it holds multiple layers of patent and regulatory exclusivity that block generic competition, and it offers clinical advantages over older antifungals that give the manufacturer pricing leverage.
What Cresemba Costs Right Now
As of January 2025, the wholesale acquisition cost (the baseline price before insurance negotiations) is $1,620.47 for fourteen 186mg capsules and $394.38 for a single IV vial. Treatment courses typically last weeks to months depending on the infection, so total costs add up quickly. For patients with commercial insurance, the manufacturer offers a copay card that can bring out-of-pocket costs down to $25 per prescription, with a cap of $4,000 in savings per year. Uninsured or underinsured patients may qualify for a separate patient assistance program.
A Small Patient Population Means Higher Prices
Cresemba is approved for two conditions: invasive aspergillosis and invasive mucormycosis. Both are serious fungal infections that primarily strike people with severely weakened immune systems, such as transplant recipients and patients undergoing chemotherapy. These infections are rare enough that Cresemba received orphan drug designation from the FDA for both uses.
Orphan drug status exists to encourage companies to develop treatments for diseases affecting small populations, where the potential sales volume alone wouldn’t justify the investment. In exchange, the manufacturer gets years of market exclusivity. Because there are relatively few patients who need the drug, the company sets a high per-unit price to recoup development costs and earn returns that a blockbuster drug with millions of patients would achieve through volume instead.
No Generic Competition Until at Least 2028
No generic version of Cresemba exists, and multiple overlapping protections keep competitors off the market. The drug’s key patents don’t expire until March 2028, and a web of FDA exclusivity periods extends even further. Pediatric exclusivity tied to newer approvals for children runs through June 2031, and additional protections under the GAIN Act (which incentivizes antifungal and antibiotic development) last until September 2027.
These exclusivity layers stack on top of each other. Even after the original orphan drug exclusivity for adult patients expired in 2022, the patents and newer pediatric designations continue to prevent generic manufacturers from entering the market. Until a generic competitor gains approval, there is no price pressure from lower-cost alternatives.
Clinical Advantages Over Older Antifungals
Cresemba isn’t the only antifungal available, but it has a meaningfully better side effect profile than voriconazole, the previous standard treatment for invasive mold infections. In the pivotal head-to-head trial (called SECURE), drug-related side effects occurred in 42% of Cresemba patients compared to 60% of those on voriconazole. Two specific problems were notably less common with Cresemba: liver-related complications (9% vs. 16%) and eye disorders like visual disturbances (15% vs. 27%).
Cresemba also covers mucormycosis, a particularly aggressive and often fatal fungal infection that voriconazole does not treat. That broader coverage, combined with fewer side effects, makes it the preferred choice for many patients and gives the manufacturer less reason to compete on price. When a drug is both safer and more versatile than alternatives, physicians will prescribe it even at a premium, and the company prices accordingly.
Complex Manufacturing and R&D Recovery
Cresemba is a prodrug, meaning the capsule or IV formulation contains a compound that converts into the active antifungal agent inside the body. This adds complexity to manufacturing. The company that originally developed it, Basilea Pharmaceutica, relied on single-source contract manufacturers for the active ingredient and key components. Having only one qualified supplier for critical steps means limited ability to shop for cheaper production and higher vulnerability to supply disruptions, both of which factor into pricing.
The development itself spanned years of clinical trials across a small, hard-to-recruit patient population. Patients with invasive fungal infections are critically ill and dispersed across specialized medical centers, making trials slow and expensive per enrolled patient. Astellas, which licensed commercialization rights, reimbursed millions of Swiss francs annually to Basilea during development. Those costs get baked into the drug’s price over its commercial lifetime.
The Broader Cost Picture
Invasive aspergillosis typically requires hospital stays averaging around 27 days, and the total cost of hospitalization for these infections is substantial and rising faster than costs for more common conditions like heart failure or pneumonia. In that context, the drug cost itself is one piece of a much larger bill. Payers and hospitals sometimes view an effective antifungal as cost-saving if it shortens ICU stays or prevents treatment failures that lead to even more expensive interventions.
That doesn’t make the price easy to absorb for individual patients, especially those who are underinsured. But it helps explain why insurers often continue to cover Cresemba despite the price tag: for the infections it treats, the alternative is often worse outcomes and higher total costs downstream.
Ways to Lower Your Out-of-Pocket Cost
If you have commercial insurance, Astellas offers a copay assistance card that reduces your cost to $25 per fill, up to $4,000 in annual savings. If you’re uninsured or underinsured, the company’s patient assistance program may provide the drug at no cost, provided you have a qualifying diagnosis and are treated by a U.S. physician. Your prescriber’s office or a specialty pharmacy can typically help you apply for either program.